Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Breslin

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Oncotarget|June 16, 2016
The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistanceSusan Breslin, Lorraine O'Driscoll
Methods in Molecular Biology (Clifton, N.J.)|October 17, 2014
Receptor tyrosine kinase targeting in multicellular spheroidsSusan Breslin, Lorraine O'Driscoll
Drug Discovery Today|October 18, 2012
Three-dimensional cell culture: the missing link in drug discoverySusan Breslin, Lorraine O'Driscoll
Computers, Informatics, Nursing : CIN|November 3, 2004
Wireless technology improves nursing workflow and communicationsSusan Breslin, William Greskovich, Fran Turisco
British Journal of Cancer|February 3, 2017
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4Susan Breslin, Michelle C Lowry, Lorraine O'Driscoll
Molecular Cancer|March 25, 2014
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerClaire Corcoran, Sweta Rani, Susan Breslin, et al.
Molecular Cancer|October 1, 2024
Editorial expression of concern: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerClaire Corcoran, Sweta Rani, Susan Breslin, et al.
Molecular Cancer|January 31, 2025
Correction: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerClaire Corcoran, Sweta Rani, Susan Breslin, et al.
Oncoimmunology|December 7, 2017
Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesiclesVanesa G Martinez, Sadhbh O'Neill, Josephine Salimu, et al.
Cancer Research|May 31, 2014
Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitorsSweta Rani, Claire Corcoran, Liam Shiels, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Oncotarget|June 16, 2016
The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistanceSusan Breslin, Lorraine O'Driscoll
Methods in Molecular Biology (Clifton, N.J.)|October 17, 2014
Receptor tyrosine kinase targeting in multicellular spheroidsSusan Breslin, Lorraine O'Driscoll
Drug Discovery Today|October 18, 2012
Three-dimensional cell culture: the missing link in drug discoverySusan Breslin, Lorraine O'Driscoll
Computers, Informatics, Nursing : CIN|November 3, 2004
Wireless technology improves nursing workflow and communicationsSusan Breslin, William Greskovich, Fran Turisco
British Journal of Cancer|February 3, 2017
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4Susan Breslin, Michelle C Lowry, Lorraine O'Driscoll
Molecular Cancer|March 25, 2014
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerClaire Corcoran, Sweta Rani, Susan Breslin, et al.
Molecular Cancer|October 1, 2024
Editorial expression of concern: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerClaire Corcoran, Sweta Rani, Susan Breslin, et al.
Molecular Cancer|January 31, 2025
Correction: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerClaire Corcoran, Sweta Rani, Susan Breslin, et al.
Oncoimmunology|December 7, 2017
Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesiclesVanesa G Martinez, Sadhbh O'Neill, Josephine Salimu, et al.
Cancer Research|May 31, 2014
Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitorsSweta Rani, Claire Corcoran, Liam Shiels, et al.
Pageof 1